Manabu Kinoshita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Manabu Kinoshita has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Hideyuki Arita
Department of Neurosurgery, Osaka International Cancer Institute, Osaka, Japan
2 shared publications - Eku Shimosegawa
Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
1 shared publication - Haruhiko Kishima
Osaka University
1 shared publication Hisahiro Tsuyuguchi
Department of Neurosurgery, Osaka City University Graduate School of Medicine, Osaka, Japan
1 shared publication- Jun Hatazawa
Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Osaka University, Osaka, Japan
1 shared publication - Junya Fukai
Department of Neurosurgery, Wakayama Medical University, Wakayama, Japan
1 shared publication
Latest Publications
- 5 November 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (suppl_6) , vi232-vi233
RTHP-37. IMPACT OF 11C-METHIONINE/FDG DURAL TRACER PET-BASED, COMPARED WITH MRI-BASED TARGET DELINEATION OF MALIGNANT GLIOMAS FOR RADIATION PLANNING
Precise delineation of target volume for radiotherapy of malignant glioma is one of the crucial processes in glioma treatment. Although MRI is the modality often chosen for this procedure, the authors’ previous research showed that combined use of 11C-methionine (MET) and 18F-fluorodeoxyglucose (FDG) PET was more accurate for glioma visualization (J Nucl Med, 2012). The aim of this study was to analyze volumetric and geometrical properties of RT-target-delineation based on MET/FDG PET and to compared them with those based on MRI. The impact of geometrical properties on progression free survival was further investigated. Twenty-five patients with a diagnosis of malignant glioma were included in our study. Three target volumes were compared, which included contrast-enhancing core lesions identified by contrast-enhanced T1 weighted images (T1Gd), high intensity lesions on T2 weighted images, and lesions showing high DS, a cell density score calculated from MET/FDG PET (> 3; hDS). T1Gd with 2.0 cm margin was able to cover the entire hDS only in 6 (24%) patients, indicating microscopic invasion of glioma cells beyond 2cm from gadolinium-enhanced core. Insufficient coverage of high DS region with RT target volume was suggested to be a risk for out-field recurrence. Higher coverage of hDS (T1Gd + 2/hDS) by T1Gd with 2 cm margin tended to positively impact overall and progression free survival. Cox regression analysis demonstrated that low coverage of hDS by T1Gd with 2 cm margin was predictive of tumor recurrence outside gadolinium-enhanced core, indicative of out-field reoccurrence. Present findings indicate that MRI is inadequate for target delineation for radiation therapy in malignant glioma treatment. Expanding additional margins to MRI based target volume often reduces this uncertainty while unnecessarily irradiated regions increase and MET/FDG PET seemed to provide more accurate information for target delineation than MRI.
- 5 November 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (suppl_6) , vi232-vi233
RTHP-37. IMPACT OF 11C-METHIONINE/FDG DURAL TRACER PET-BASED, COMPARED WITH MRI-BASED TARGET DELINEATION OF MALIGNANT GLIOMAS FOR RADIATION PLANNING
Precise delineation of target volume for radiotherapy of malignant glioma is one of the crucial processes in glioma treatment. Although MRI is the modality often chosen for this procedure, the authors’ previous research showed that combined use of 11C-methionine (MET) and 18F-fluorodeoxyglucose (FDG) PET was more accurate for glioma visualization (J Nucl Med, 2012). The aim of this study was to analyze volumetric and geometrical properties of RT-target-delineation based on MET/FDG PET and to compared them with those based on MRI. The impact of geometrical properties on progression free survival was further investigated. Twenty-five patients with a diagnosis of malignant glioma were included in our study. Three target volumes were compared, which included contrast-enhancing core lesions identified by contrast-enhanced T1 weighted images (T1Gd), high intensity lesions on T2 weighted images, and lesions showing high DS, a cell density score calculated from MET/FDG PET (> 3; hDS). T1Gd with 2.0 cm margin was able to cover the entire hDS only in 6 (24%) patients, indicating microscopic invasion of glioma cells beyond 2cm from gadolinium-enhanced core. Insufficient coverage of high DS region with RT target volume was suggested to be a risk for out-field recurrence. Higher coverage of hDS (T1Gd + 2/hDS) by T1Gd with 2 cm margin tended to positively impact overall and progression free survival. Cox regression analysis demonstrated that low coverage of hDS by T1Gd with 2 cm margin was predictive of tumor recurrence outside gadolinium-enhanced core, indicative of out-field reoccurrence. Present findings indicate that MRI is inadequate for target delineation for radiation therapy in malignant glioma treatment. Expanding additional margins to MRI based target volume often reduces this uncertainty while unnecessarily irradiated regions increase and MET/FDG PET seemed to provide more accurate information for target delineation than MRI.
- 5 November 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (suppl_6) , vi192
NIMG-73. RADIOMICS OF GLIOBLASTOMA FOR PREDICTING MGMT PROMOTOR METHYLATION STATUS AND PROGNOSIS
O-6-methylguanine-DNA methyltransferase promotor methylation (pMGMT-met) is identified as a favorable prognostic factor for glioblastoma (GBM) and patients with GBM containing pMGMT-met benefit from temozolomide. On the other hand, radiomic analysis that rely on quantitative texture feature of radiological images has rapidly emerged in the field of neuro-oncology. In this study, the authors attempted to build a radiomic-based prediction model for pMGMT-met status of GB. Building a prognostic model was further attempted by radiomic analysis of conventional MRI. Preoperative MRI (non-enhanced and enhanced T1WI, T2WI, and FLAIR) from 207 newly diagnosed GBM (nGMB) patients were included in this study. Total of 489 texture features including first order feature (histogram of pixels), second order feature (Gray level co-occurrence matrix and Grey level run length matrix) from 166 date sets and location data from 187 data set were collected. Predictive modeling for pMGMT-met status was performed based on LASSO regression with 10-fold cross-validation which was repeated 5 times. Supervised component principal analysis was used for prognosis prediction. One hundred and four cases were pMGMT-met and 103 patients were MGMT promotor unmethylated (pMGMT-unmet). Predictive accuracy of pMGMT-met status was 68% modeled by 28 significant radiomic features. Furthermore, 20 radiomic features correlated with prognosis the analyzed cohort was categorized into high risk and low risk group by use of radiomic score (P value <0.0069). Radiomic score and pMGMT status were independent prognostic factors. Finally, significant survival difference was observed between radiomic high risk and pMGMT-unmet group, intermediated group (which group consists of radiomic low risk and pMGMT-unmet or radiomic high risk and pMGMT-met), and radiomic low risk and pMGMT-met group (P value <0.0001). In conclusion, the current study revealed that biological characteristics of GBM is embedded in radiomic features, recovery of which information could be beneficial for GBM patient care.
- 5 November 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (suppl_6) , vi192
NIMG-73. RADIOMICS OF GLIOBLASTOMA FOR PREDICTING MGMT PROMOTOR METHYLATION STATUS AND PROGNOSIS
O-6-methylguanine-DNA methyltransferase promotor methylation (pMGMT-met) is identified as a favorable prognostic factor for glioblastoma (GBM) and patients with GBM containing pMGMT-met benefit from temozolomide. On the other hand, radiomic analysis that rely on quantitative texture feature of radiological images has rapidly emerged in the field of neuro-oncology. In this study, the authors attempted to build a radiomic-based prediction model for pMGMT-met status of GB. Building a prognostic model was further attempted by radiomic analysis of conventional MRI. Preoperative MRI (non-enhanced and enhanced T1WI, T2WI, and FLAIR) from 207 newly diagnosed GBM (nGMB) patients were included in this study. Total of 489 texture features including first order feature (histogram of pixels), second order feature (Gray level co-occurrence matrix and Grey level run length matrix) from 166 date sets and location data from 187 data set were collected. Predictive modeling for pMGMT-met status was performed based on LASSO regression with 10-fold cross-validation which was repeated 5 times. Supervised component principal analysis was used for prognosis prediction. One hundred and four cases were pMGMT-met and 103 patients were MGMT promotor unmethylated (pMGMT-unmet). Predictive accuracy of pMGMT-met status was 68% modeled by 28 significant radiomic features. Furthermore, 20 radiomic features correlated with prognosis the analyzed cohort was categorized into high risk and low risk group by use of radiomic score (P value <0.0069). Radiomic score and pMGMT status were independent prognostic factors. Finally, significant survival difference was observed between radiomic high risk and pMGMT-unmet group, intermediated group (which group consists of radiomic low risk and pMGMT-unmet or radiomic high risk and pMGMT-met), and radiomic low risk and pMGMT-met group (P value <0.0001). In conclusion, the current study revealed that biological characteristics of GBM is embedded in radiomic features, recovery of which information could be beneficial for GBM patient care.